A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Rivaroxaban
MessageFor Specimen Integrity during Extreme Weather see the “Lockbox Usage in Extreme Weather” document at the top of this page.
Test Code
RIVARX
CPT Codes
80299
Preferred Specimen
1 mL plasma collected in a 3.2% sodium citrate (light blue-top) tube
Patient Preparation
Collect samples 2-4 hours post dose (peak)
Minimum Volume
0.5 mL
Transport Temperature
Frozen
Specimen Stability
Room temperature: Unacceptable
Refrigerated: Unacceptable
Frozen: 28 days
Refrigerated: Unacceptable
Frozen: 28 days
Methodology
Chromogenic
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Wed, Fri a.m.; Report available: Next day
Reference Range
Dosage |
Peak mcg/L (at steady state) |
Trough* mcg/L |
20 mg qD | 182-408 | 3-153 |
15 mg qD | 180-408 | 2-161 |
10 mg qD | 91-196 | 1-38 |
Clinical Significance
Rivaroxaban is an oral factor Xa inhibitor that is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also indicated for the treatment, prophylaxis, or the reduction in the risk of reoccurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE). Rivaroxaban does not need to be monitored routinely, however, exceptions may include determination of failure of therapy vs. poor compliance, or potential dose adjustment required for renal or hepatic dysfunction.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
Last Updated: December 6, 2021